Funds affiliated with Nantahala purchased shares from the OrbiMed Sellers under a stock purchase agreement; the company entered into a registration rights agreement with the Purchasers.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Sean E. Browne
Also a director
President and Chief Executive Officer and Director
|
60 | Not stated | Not stated | $1,351,676 | |
|
Scott C. Neils
Chief Financial Officer and Assistant Secretary
|
42 | Not stated | Not stated | $939,369 | |
|
Mark A. Schallenberger
Chief Operating Officer
|
40 |
Since 2025
1 year
|
2010 | $1,110,531 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Funds affiliated with Nantahala purchased shares from the OrbiMed Sellers under a stock purchase agreement; the company entered into a registration rights agreement with the Purchasers.
Purchased shares of common stock from the OrbiMed Sellers under the April 10, 2025 stock purchase agreement (73,114,592 shares in aggregate at $0.42 per share).
Investor Rights Agreement granting governance and other rights (director nomination, special approval, rights of first refusal), terminated by the company on April 15, 2025.
Agreement under which the company granted director nomination rights as lead investor of the 2022 private placement; the nomination rights terminated October 7, 2024, and a corporate opportunities provision remains in place.
Loading...